Gapping up In reaction to strong earnings/guidance: SYNA +20.6%, (also acquires Renesas SP Drivers; co will pay a purchase price of ~JPY48.5B ($475 mln) for 100% of Renesas SP Drivers, based on JPY52.5B ($515 mln) enterprise value. The acquisition will be immediately accretive to Synaptics' non-GAAP EPS), ULTA +11.6%, RMBS +7.2%, (also signs comprehensive license agreement with Qualcomm (QCOM)) HRB +3.8%, SPWH +2.1%
Select metals/mining stocks trading higher: AUY +1.1%, AG +0.8%, NEM +0.5%.
Other news: NAVB +8.9% (Lymphoseek injection demonstrates preferential accumulation in tumor-positive sentinel lymph nodes in post-hoc analysis), OSUR +7.2% (announces new co-promotion agreement for OraQuick HCV rapid antibody test), PTLA +7% (announces positive Phase 2 data with FDA-designated breakthrough therapy Andexanet Alfa and Enoxaparin), SPEX +6.7% (and Charter Communications (CHTR) file joint stipulation of dismissal), END +5% (cont strength following guidance), PSEC +4.9% (announces no restatement of historical financial statements based on discussions with the Office of the Chief Accountant of the SEC ), AMRN +3.3% (announces publication of case study results describing reductions in multiple lipid parameters for individual hyperlipidemic patients switched to Vascepa), INFY +2.9% (still checking), ITRN +2.8% (thinly traded, still checking), PBR +2.4% (still checking), GHDX +2.2% (announces positive topline results of second large, independent validation study of Oncotype DX in DCIS breast cancer), CRDC +2% (announced completion of laparoscopic appendectomy procedure with virtually no perceptible scar), NKTR +1.6% (FDA advisory committee to discuss peripherally-acting opioid receptor antagonists - halted), BSX +0.9% (announces clinical study results demonstrate therapeutics advantages of the Boston Scientific Vercise DBS System for patients with Parkinson's disease), BLRX +0.9% (receives notice of allowance for US Patent covering novel treatment for celiac disease ), PGNX +0.8% (FDA advisory committee to consider and provide recommendations regarding peripherally-acting opioid receptor antagonists - halted).
Analyst comments: ANGI +3.6% (upgraded to Buy at Wunderlich), MU +2.7% (upgraded to Buy from Underperform at BofA/Merrill), MRVL +1.1% (upgraded to Buy from Neutral at Nomura), AMZN +1% (added to Conviction Buy list at Goldman), SNDK +1% (upgraded to Buy from Underperform at BofA/Merrill), DSX +1% (upgraded to Equal Weight from Underweight at Barclays)